NascaCell Technologies AG
NascaCell Technologies AG receives funding from EUROTRANS-BIO for the development of lab-on-a-chip systems for aptamer development and multiplex analysis of biomolecular interactions
NascaCell Technologies AG / Miscellaneous Release of a Corporate-announcement, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Munich, March 13, 2007 – EUROTRANS-BIO, an initiative of several European countries to support transnational R&D efforts, funds an innovative approach to develop automated microfluidic lab-on-a-chip systems. NascaCell will receive up to € 397.000 financial support for its contribution to the project. ARTAMIS is a cross-national cooperation between five French and German biotechnology companies and universities: Genewave SAS (Palaiseau, France), NascaCell Technologies AG (Munich, Germany), Mildendo GmbH (Jena, Germany) GODMAP-CNRS (Gif-sur-Yvette, France), and ESPCI-CNRS (Paris, France). This 3-year-project has an overall budget of €2.4 million and will be supported from the OSEO and BmBF national agencies, respectively. The goal of the ARTAMIS project is the combination and integration of leading edge technologies such as microfluidics, nanoparticles, multiplex analyses, real time detection and aptamers in miniaturized automated chip-based systems to analyse biomolecular interactions and to generate aptamers. Lab-on-a-chip systems are devices that integrate multiple laboratory functions on a single chip of only millimeters to a few square centimeters in size and which are capable of handling extremely small fluid volumes down to pico liters. 'We are very pleased that we are part of such an excellent cluster of experts dedicated to the development of revolutinary technologies.' said Dr. Michael Blind, CSO of NascaCell. 'It is exciting which possibilities could be provided by scaling down complex laboratory processes to intelligent devices composed of micro- and nanostructures that open new dimensions of parallel processing, multiplex analysis or detection sensitivity while reducing the consumption of reagents by factors of 100 to 1000. This concept would significantly enhance the power of aptamer selections and make targets accessible which are currently out of reach for aptamers, antibodies or similar technologies.' About NascaCell Technologies AG – www.nascacell.com NascaCell Technologies AG, based in Munich, is a global leading provider of a new generation of biomolecules. With the innovative Aptamer and MicrobodyTM technologies, the company supports customers in the target validation and drug discovery R&D areas. NascaCell also develops a line of products and drug development candidates based on the Microbody™ technology. About EUROTRANS-BIO – www.eurotransbio.net The EUROTRANS-BIO, a EU-cofunded initiative, is born from the will of European member states and regions - Austria, Finland, France, Germany, Spain (Basque Country) and The Netherlands- to work together in order to support trans-national R&D private/private and private/public co-operations between companies, especially SMEs, and academic labs by coordinating their national or regional public funding programmes. Thus, the goal of EUROTRANS-BIO is to foster economic and academic biotech players in sharing risks, costs and skills related to innovation in order to develop in a more efficient way new products and technologies that could reach the market in the short/medium term. Contact: InvestorPress GmbH Georg Breu Phone: +49(0)89 55 96 98 75 info@investorpress.de DGAP 13.03.2007 ----------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found